Bextra, Vioxx Require Stronger Warnings, Additional Study, Cmte. Finds
Executive Summary
Pfizer's Bextra requires additional clinical trials to clarify an observed cardiovascular signal, a joint FDA advisory committee on COX-2 inhibitor safety said
You may also be interested in...
Vioxx Importation On The Horizon? Health Canada Open To Rofecoxib Return
Health Canada appears open to the reintroduction of Merck's COX-2 inhibitor Vioxx, Health Canada Manager of Marketed Pharmaceuticals Marc Berthiaume indicated during a July 7 media call
Vioxx Importation On The Horizon? Health Canada Open To Rofecoxib Return
Health Canada appears open to the reintroduction of Merck's COX-2 inhibitor Vioxx, Health Canada Manager of Marketed Pharmaceuticals Marc Berthiaume indicated during a July 7 media call
Intra-Class Comparisons Could Help Drugs With Safety Issues – FDA’s Temple
Drugs with potential safety concerns could benefit from demonstrating an efficacy advantage over other agents in the same class, FDA Center for Drug Evaluation & Research Office of Medical Policy Director Robert Temple suggested June 28